Business Wire

Biocytogen Lists on the Main Board of HKEX, Aiming to Become the Headstream of New Drugs

Share

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) announced the company’s official listing on the Main Board of the Stock Exchange of Hong Kong. Government representatives, shareholders, agencies, collaborative partners, and employee representatives attended the listing ceremony. In total, 21.76 million shares were offered globally with a price of HK$ 25.22 per share. The net proceeds from the Global Offering will be approximately HK$ 471.1 million.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220901005536/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Biocytogen's listing ceremony (Photo: Business Wire)

Since its establishment in 2009, Biocytogen has established a series of genetically modified animal and cell models using advanced proprietary technologies, including target humanized mice and severely immunodeficient mice. The company harnesses these specialized models to provide preclinical pharmacology evaluation services for global pharmaceutical/biotech companies. These products and services greatly accelerate the research and development of novel drugs.

Biocytogen’s proprietary size-unlimited, precise chromosome engineering (SUPCE) technology, which was developed over a period of 6 years, was applied to generate a series of fully human antibody mice (RenMiceTM), including RenMabTM and RenLite®. The company has developed 5 core antibody development platforms using RenMiceTM, including a fully human monoclonal antibody discovery platform, bispecific antibody discovery platform, bispecific ADC platform, GPCR antibody platform and TCR-mimic antibody platform, which form the core competitiveness of Biocytogen’s antibody drug discovery capability. The company’s RenMiceTM-based “Project Integrum”, a large-scale antibody discovery and development program launched in 2020, involves deriving knock-out RenMiceTM, target verification and antibody discovery for 1000+ potential antibody-druggable targets. With these 5 antibody platforms, Biocytogen plans to continuously produce novel antibody drug molecules that can be licensed or co-developed with global pharmaceutical/biotech companies. Over the past two years, the company has generated 1000+ target gene knock-out RenMiceTM, with 300+ targets undergoing antibody screening, 240+ targets with hits molecules identified, and PCCs obtained for nearly 20 targets. Biocytogen strives to become the headstream of novel antibody drugs.

With gene-edited animal and cell models serving as the foundation, Biocytogen has developed an innovative evidence-based in vivo drug efficacy and safety screening process. These preclinical discovery and pharmacology platforms have supported the establishment of 10+ preclinical and clinical pipelines, including monoclonal antibodies, bispecific antibodies and bispecific ADCs; 3 products have been out-licensed and/or entered co-development. The company’s leading products, YH003 (CD40 mAb) and YH001 (CTLA-4 mAb), are currently in phase II multi-regional clinical trials and global drug development, with their phase I studies showing excellent safety profiles and promising preliminary anti-tumor activities.

Biocytogen has developed over 2500 innovative animal models since 2013 and these models have been sold to more than 20 countries around the world. In the future, 1000+ innovative models are expected to be successfully developed and put into the market. Biocytogen has completed more than 500 preclinical antibody drug evaluation projects for more than 200 biopharmaceutical companies, including many of the top 10 global biopharmaceutical companies. The company has licensed the RenMiceTM platform to 14 companies, including Merck Healthcare KGaA, BeiGene, Xencor and Innovent; 32 projects have initiated. Additionally, the company has reached 24 preclinical antibody co-development or license agreements with 15 companies, including Merck Healthcare KGaA, RemeGen, China Resources Biopharm, Nanjing Chia-Tai Tianqing Pharmaceutical Company (NJCTTQ) and LiberoThera. The company is also collaborating with partners such as Remgen, TRACON and Gene Quantum to co-develop preclinical and clinical antibody drug pipelines.

When picturing the future of Biocytogen, Dr. Yuelei Shen, Founder, Chairman and CEO, said: “Biocytogen’s fast growth and development is impossible without the efforts of all employees, the strong support of local government, shareholders, and global collaborators. Listing on the Hong Kong Stock Exchange is the recognition of our company’s past achievements and the trust for our company’s future growth from the capital market. We believe that with the help of the HKEX listing, Biocytogen will further strengthen innovative research and development, continue to produce high-quality products and services, and persist in flexible and mutually beneficial business collaboration models. As a biotechnology company rooted in China with a global view, we strive to further accelerate the globalization of the company’s business and give back to our shareholders, employees, and society with excellent achievements and financial return.”

About Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Using its proprietary RenMabTM /RenLite® mice platforms for fully human monoclonal and bispecific antibody development, Biocytogen has integrated its in vivo drug efficacy screening platforms and strong clinical development expertise to streamline the entire drug development process. Biocytogen is undertaking a large-scale project to develop antibody drugs for more than 1000 targets, known as Project Integrum, and has entered ongoing collaborations with dozens of partners worldwide to produce a variety of antibody drugs. The company's pipeline includes 12 core products, among which two products are in phase II multi-regional clinical trials and two products are in phase I. Headquartered in Beijing, Biocytogen has branches in Haimen Jiangsu, Shanghai and Boston, USA. For more information, please visit www.biocytogen.com.cn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Assets: BD-Licensing@biocytogen.com
Media: pr@bbctg.com.cn

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

O-RAN ALLIANCE Announces Key Topics at the Open RAN Summit at Fyuz, Global PlugFest Fall 2022 and a New Set of O-RAN Demos26.9.2022 19:45:00 CEST | Press release

O-RAN ALLIANCE: Key topics at the Open RAN Summit @ Fyuz 2022 brought by the O-RAN ALLIANCE The Open RAN Summit @ Fyuz, powered by O-RAN ALLIANCE and Telecom Infra Project, will take place in Madrid on October 25-26, 2022. As a main partner of the event, O-RAN ALLIANCE brings key topics to the agenda and invites utmost erudite speakers. Join the event to get the latest news and views on: O-RAN ALLIANCE and TIP cooperation Established operators worldwide showcasing how they are overcoming Open RAN challenges and moving forward with deployments Open RAN cloudification options and realities Achievements and challenges on the open RAN supply side, along with insights into value chain evolution Rich variety of Open RAN deployment paths tailored to meet diverse operator’s needs How the testing and integration work is critical to making Open RAN a success What’s behind the hype of the RAN Intelligent Controllers and how an empowered ecosystem delivers customized operator value And many more i

Boomi Appoints Mark Fields to Its Board of Directors26.9.2022 18:00:00 CEST | Press release

Boomi™, the intelligent connectivity and automation leader, today announced the appointment of former CEO of Ford Motor Company Mark Fields as an independent, non-executive member of its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005019/en/ Boomi Appoints Mark Fields to Board of Directors (Graphic: Business Wire) “As Boomi continues its rapid growth, we’re excited to attract sought-after leaders to join our mission to make the world a better place by connecting everyone to everything, anywhere,” said David Meredith, CEO at Boomi. “Mark’s exceptional track record as a leader, advisor and visionary — coupled with our award-winning technology and innovation — helps position Boomi to deliver superior outcomes for even more customers.” Mark Fields As former CEO of Ford Motor Company, Fields brings three decades of experience driving innovation and business transformation initiatives across multi-bill

ONWARD Announces Appointment of Vivian Riefberg to Board of Directors26.9.2022 17:30:00 CEST | Press release

ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative therapies to restore movement, independence, and health in people with spinal cord injury, today announced the appointment of Vivian Riefberg as a non-executive member of its Board of Directors. Ms. Riefberg will join the Board immediately and will serve on its Compensation Committee. Her appointment to the Board will be presented for shareholder approval at the next Annual General Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005494/en/ Vivian Riefberg joins the ONWARD Medical Board of Directors (Photo: Business Wire) “Vivian Riefberg is a distinguished expert in health care, government, and strategy. I am excited and honored to welcome her to our Board”, said Dave Marver, Chief Executive Officer. “Vivian brings a rich understanding of the institutions with which we will collaborate to bring our novel therapies to market

ComTech Gold $CGO Becomes the First 100% Gold Backed Token to Receive Shariah Certification in the MENA Region26.9.2022 17:25:00 CEST | Press release

ComTech FZCO receives Shariah Compliance Certification for ComTech Gold Token (CGO), becoming the first in industry to be awarded a Shariah certification for Gold tokenization product in the Region. Shariah certification (Fatwa) was issued by Amanie Advisors Ltd, an entity specialising in field of Shariah-compliant investments and Islamic finance solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005591/en/ ComTech Gold $CGO receives Shariah Certification from Amanie Advisors (Photo: AETOSWire) ComTech FZCO, a Dubai-based company redefining tokenization infrastructure (for real-world assets), started with digitization of Gold powered by XDC Network. ComTech Gold ‘CGO’ is listed on Global Exchanges like LBank, Bitrue. Investors can buy CGO by opening an account with these exchanges. Investors can hold tokens within the exchange wallets or with any of the Internationally accepted wallets like D’cent, Guarda, or th

Actylis Debuts, Signaling the Creation of an Integrated Global Specialty Ingredients Manufacturing and Sourcing Powerhouse26.9.2022 17:00:00 CEST | Press release

Actylis, a leading global manufacturer and sourcing expert of critical raw materials and performance ingredients for the life sciences and specialty chemicals markets, made its debut today. The new company combines Aceto and 10 industry specialists into an integrated global ingredient powerhouse. Actylis (“Ac-till-iss”) is the culmination of an ambitious initiative launched several years ago to address the major unmet need for better and more dependable access to critical raw materials and performance ingredients essential for the manufacture of highly regulated products in key industries. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220926005021/en/ To achieve this goal, Actylis has integrated leading specialty ingredient manufacturing and sourcing companies, including A&C, A&C Bio Buffer, Aceto, Biotron Laboratories, Cascade Chemistry, Finar, Inter-Actifs, IsleChem, Pharma Waldhof, Syntor Fine Chemicals and Talus into on

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom